CDK2 and breast carcinoma: It was found in breast cancer cells that are resistant to palbociclib which the transcriptions of AP-1 and C-FOS were increased, and AP-1 blockade in combination with palbociclib could effectively inhibit cell proliferation and reduce pRb and CDK2 levels as compared to single agent treatment (77).